Viemed Healthcare Q3 2026 earnings

VMD · 2026-11-04 17:03 AMC ET · 8-K on SEC

Record revenue and improved profitability driven by diversified platform growth and operating leverage.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$80.7M+12.2%+3.3%Ex. 99.1, income statement
EPS (GAAP)$0.11+22.2%+67.8%Ex. 99.1, income statement
EPS (adjusted)$0.12+33.3%+67.8%Ex. 99.1, income statement
Net income$4.6M+32.0%+67.8%Ex. 99.1, income statement
Adj. EBITDA$17.1M+5.8%+24.4%Ex. 99.1, income statement
Adj. EBITDA margin21.1%+5.8%+3.5 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Ventilator rental revenue$37.5M+7.4%46.5%Supported by higher average patient volumes
PAP therapy patients43,861+37.5%—16.0% sequential increase
Sleep resupply patients40,918+22.1%—10.5% sequential increase

Margins and costs

  • Gross margin 57.3% (prior 57.3%, change 0.0 pp)
  • Operating expenses $38,877 (+8.9% YoY)
  • One-offs in the quarter Loss (gain) on disposal of property and equipment: $412k; Transaction costs: $0; Impairment of assets: $0
  • Effective tax rate 30.2% (prior-year 29.9%, year-to-date 30.2%)
  • Non-GAAP bridge Depreciation & amortization, Interest expense, Stock-based compensation, Transaction costs, Income tax expense

KPIs

MetricActualPrior quarterPrior yearChange
Net cash provided by operating activities$11.5M$15.9M$3.5M+67.8% vs prior quarter
Free cash flow$4.0M$8.6M$3.5M-53.5% vs prior quarter
Ventilator patient count12,55212,63512,070-0.7% vs prior quarter
Cash balance$9.7M$10.7M$10.7M-9.3% vs prior quarter

Guidance

MetricGuidePrior guideChange
Net revenue$316M - $320M$314M - $320MRaised low end by $2M
Adjusted EBITDA$64M - $66M$64M - $68MNarrowed range by $2M
Net capital expenditures8.0% - 9.0% of net revenue8.5% - 10.0% of net revenueLowered range by 50 bps

What drove it

  • Revenue story Ventilator rental revenue increased 7.4% year over year; PAP therapy patients increased 37.5% year over year; Sleep resupply patients increased 22.1% year over year.
  • EPS story Net income attributable to Viemed increased 32.0% year over year and 67.8% sequentially.
  • One-off check Loss (gain) on disposal of property and equipment: $412k (2026) vs $598k (2025)

The good

  • Record revenue of $80.7M
  • Adjusted EBITDA margin increased to 21.1%
  • Net income attributable to Viemed increased 67.8% sequentially

The bad

  • Free cash flow decreased 53.5% sequentially to $4.0M
  • Ventilator patient count decreased 0.7% sequentially

The ugly

  • none

Open questions

  • The release does not disclose the specific revenue mix by segment (e.g., ventilator vs. PAP vs. resupply) or the revenue contribution of the Lehan acquisition.
  • The release does not provide a reconciliation of Adjusted EBITDA to GAAP net income.
Full release

Viemed Healthcare (VMD) earnings release, November 4, 2026

Viemed Healthcare, Inc. (VMD) · Form 8-K, Item 2.02 · Filed · SEC filing

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, announced today that it has reported its financial results for the three and nine months ended September 30, 2026, and updated guidance for the full year ending December 31, 2026.

Third Quarter 2026 Financial and Operational Highlights (all dollar amounts are USD):

• Net revenue for the quarter ended September 30, 2026 totaled a Company record $80.7 million, an increase of $8.8 million, or 12.2%, compared with the prior-year quarter, and 3.3% sequentially.

• Net income attributable to Viemed totaled $4.6 million, or $0.11 per diluted share, an increase of 32.0% compared to $3.5 million, or $0.09 per diluted share, in the prior-year quarter, and a 67.8% sequential increase from $2.8 million in the second quarter of 2026. Net income attributable to Viemed represented 5.7% of net revenue, compared to 3.5% in the preceding quarter.

• Adjusted EBITDA totaled $17.1 million, an increase of 5.8% year over year and 24.4% sequentially. Adjusted EBITDA as a percentage of net revenue increased to 21.1%, compared to 17.6% in the second quarter of 2026, representing an improvement of approximately 350 basis points.

• Ventilator rental revenue increased 7.4% year over year to $37.5 million, supported by higher average patient volumes. The Company's period-end ventilator patient count totaled 12,552 as of September 30, 2026.

• PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861 during the third quarter. Sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918.

• Net cash provided by operating activities totaled $11.5 million for the quarter and $53.9 million for the trailing twelve months ended September 30, 2026. Free cash flow totaled $4.0 million for the quarter and $26.1 million for the trailing twelve months ended September 30, 2026.

• The Company ended the quarter with $9.7 million in cash, $12.0 million in working capital, and approximately $46 million available under its existing credit facilities. During the quarter, the Company repaid $2.1 million of term debt and repurchased 115,000 common shares for approximately $1.0 million (excluding taxes).

Updated Full Year 2026 Guidance (all dollar amounts are USD):

Based on third quarter performance and increased visibility into the remainder of the year, the Company is raising the low end of its revenue guidance, narrowing its Adjusted EBITDA guidance range, and lowering its net capital expenditure outlook. The updated guidance reflects continued growth across the Company's diversified platform, anticipated sequential improvement in revenue and Adjusted EBITDA in the fourth quarter, and reduced capital intensity as less capital-intensive product and service offerings contribute a greater share of revenue.

• Net revenue is expected to be in the range of $316 million to $320 million, compared with the previous range of $314 million to $320 million.

• Adjusted EBITDA is expected to range from $64 million to $66 million, compared with the previous range of $64 million to $68 million.

• Net capital expenditures are now expected to range from 8.0% to 9.0% of net revenue, compared with the previous range of 8.5% to 10.0%.

This outlook excludes the impact of potential future acquisitions or other strategic transactions. See “Use of Non-GAAP Financial Information and Financial Guidance” below for further information about non-GAAP financial measures and non-GAAP financial guidance.

Casey Hoyt, Viemed’s CEO, commented:

“Viemed delivered another record quarter, with revenue reaching $80.7 million and continued growth across our respiratory, sleep, and women's health businesses. This marks our first full year-over-year quarterly comparison following the Lehan acquisition, and achieving double-digit revenue growth underscores the strength of our increasingly diversified platform and the opportunities ahead of us.”

“We are particularly pleased with the improvement in profitability this quarter. Our attributable net income increased 68% sequentially, while Adjusted EBITDA grew 24%, significantly outpacing revenue growth and demonstrating improved operating leverage. These results reflect the progress we anticipated following our investments earlier this year, and we see additional opportunities to improve efficiency as those initiatives mature. We remain focused on expanding our reach, delivering high-quality patient care, and building on this momentum as we finish the year.”

Conference Call Details

The Company will host a conference call to discuss third quarter results on Thursday, November 5, 2026, at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

877-407-6176 (US Toll-Free)

+1 201-689-8451 (International)

Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=AAf4KB3V

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of home medical equipment and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. Viemed’s model emphasizes efficient, high-quality care delivered in the home through a combination of high-touch clinical support and technology-enabled services, including therapy, education, and counseling provided by our clinical practitioners. For more information, visit our website at www.viemed.com.

For further information, please contact:

Investor Relations ir@viemed.com

Trae Fitzgerald

Chief Financial Officer

337-504-3802

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue80,67371,914234,184194,099
Cost of revenue34,48130,569100,11782,744
Gross profit46,19241,345134,067111,355
Operating expenses
Selling, general and administrative35,50831,919107,43289,147
Research and development5017751,5842,419
Stock-based compensation2,4762,1806,9596,832
Depreciation and amortization3923971,1681,098
Loss (gain) on disposal of property and equipment4124761,366-2,528
Other income, net-59-44-161-191
Income from operations6,9625,64215,71914,578
Non-operating income and expenses
Loss from investments162
Interest expense, net177507730818
Net income before taxes6,7855,13514,82713,760
Provision for income taxes2,0481,5354,4774,200
Net income4,7373,60010,3509,560
Net income attributable to noncontrolling interest9987366265
Net income attributable to Viemed Healthcare, Inc.4,6383,5139,9849,295
Net income per share
Basic0.120.090.260.24
Diluted0.110.090.240.23
Weighted average number of common shares outstanding:
Basic38,102,06438,638,66038,257,51839,190,666
Diluted41,192,31340,495,76140,975,36241,086,178

Income Statement

For the quarter ended — (Expressed in thousands of U.S. Dollars)

September 30, 2026June 30, 2026March 31, 2026December 31, 2025September 30, 2025June 30, 2025March 31, 2025December 31, 2024
Net income attributable to Viemed Healthcare, Inc.4,6382,7642,5825,6393,5133,1572,6254,316
Add back:
Depreciation & amortization7,7187,5207,6217,5707,5396,8916,6136,366
Interest expense, net177248305364507132179147
Stock-based compensation(a)2,4762,0322,4512,3002,1802,3412,3111,521
Transaction costs(b)74139847538511
Income tax expense2,0481,1511,2782,1911,5351,7139521,881
Adjusted EBITDA17,05713,71514,31118,20316,12114,28712,76514,242

Balance Sheet

At September 30, 2026 — (Unaudited)

At September 30, 2026At December 31, 2025
Current assets
Cash and cash equivalents9,67613,501
Accounts receivable, net34,88725,586
Inventory4,5525,047
Income tax receivable227
Prepaid expenses and other assets10,1754,132
Total current assets59,29048,493
Long-term assets
Property and equipment, net75,59678,775
Operating lease right-of-use assets4,2423,580
Equity investments3,1842,794
Deferred tax asset5,2895,289
Identifiable intangibles, net1,0951,285
Goodwill58,93858,938
Total long-term assets148,344150,661
TOTAL ASSETS207,634199,154
Current liabilities
Trade payables10,6287,333
Deferred revenue8,0157,520
Income taxes payable1,925
Accrued liabilities24,81823,910
Operating lease liabilities, current portion1,4271,203
Current portion of long-term debt5111,090
Total current liabilities47,32441,056
Long-term liabilities
Accrued liabilities977922
Operating lease liabilities, less current portion2,8352,364
Long-term debt4,51011,291
Total long-term liabilities8,32214,577
TOTAL LIABILITIES55,64655,633
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,053,094 and 38,019,082 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively17,93716,912
Additional paid-in capital19,27721,742
Retained earnings112,875102,891
TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY150,089141,545
Noncontrolling interest in subsidiary1,8991,976
TOTAL SHAREHOLDERS' EQUITY151,988143,521
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY207,634199,154

Cash Flow

Nine Months Ended September 30, — (Unaudited)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities
Net income10,3509,560
Adjustments for:
Depreciation and amortization22,85921,043
Stock-based compensation expense6,9596,832
Loss (gain) on disposal of property and equipment1,366-2,528
Amortization of deferred financing costs198121
Deferred income tax expense2,729
Loss from other investments162
Changes in working capital:
Accounts receivable, net-9,301-670
Inventory495-163

Cash Flow

For the quarter ended — (Expressed in thousands of U.S. Dollars; unaudited)

TTM – September 30, 2026For the quarter ended – September 30, 2026For the quarter ended – June 30, 2026For the quarter ended – March 31, 2026For the quarter ended – December 31, 2025
Net cash provided by operating activities53,90111,48715,9028,07118,441
Less:
Purchase of property and equipment-32,525-8,616-8,460-6,712-8,737
Proceeds from sale of property and equipment4,6801,1541,1741,2271,125
Net CAPEX-27,845-7,462-7,286-5,485-7,612
Free cash flow26,0564,0258,6162,58610,829

Forward-Looking Statements... (truncated) of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's 2026 net revenue, Adjusted EBITDA and net capital expenditure guidance, anticipated patient and revenue growth, expected improvements in operating efficiency, and profitability, anticipated benefits from technology, purchasing and operational initiatives, capital allocation priorities, share repurchases and future cash generation, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; changes in U.S. trade policies and retaliatory responses from other countries, including tariffs; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; the use of artificial intelligence technologies; as well as other general economic, market and business conditions; and other factors beyond our control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at www.sedarplus.ca. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

Use of Non-GAAP Financial Information and Financial Guidance

This press release includes references to financial measures that are calculated and presented using methodologies other than those in accordance with generally accepted accounting principles in the United States (“GAAP”), including Adjusted EBITDA and free cash flow. Any non-GAAP financial measures presented herein are intended to supplement, and not to be considered superior to or as a substitute for, the Company’s consolidated financial statements prepared in accordance with GAAP. These non-GAAP financial measures exclude significant expense and income items required by GAAP, and are subject to inherent limitations, including the exercise of judgment by management regarding which items to exclude or include. Non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. The reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the tables accompanying this release.... (truncated)non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company’s non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future operating results. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. As a result, reconciliation of the non-GAAP financial guidance to the most directly comparable GAAP measure is not available without unreasonable effort. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. The variability of the specified items may have a significant and unpredictable impact on the Company’s future GAAP results. The Company’s financial guidance in this press release excludes the impact of potential future acquisitions or strategic transactions and any items that have not yet been identified or quantified. This guidance is subject to risks and uncertainties inherent in all forward-looking statements, as outlined above.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Viemed Healthcare earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.